Government of Nepal Ministry of Health and Population Department of Drug Administration National Medicines Laboratory Quality and Method Validation Section

Analytical profile of Empagliflozin and LinagliptinTablets

Analytical Profile No.: Empa Lina 080/81/AP 157

Empagliflozin and Linagliptin Tablets contains not less than 90.0% and not more than 110.0% of the stated amount of Empagliflozin and Linagliptin.

Usual Strength: Empagliflozin 25 mg and Linagliptin 5 mg

Empagliflozin 10 mg and Linagliptin 5 mg

1. Identification:

In the Assay, the principle peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the certified reference solution.

2. Dissolution: *Determine by liquid chromatography*

2.1 Dissolution Parameters:

Apparatus: Paddle

Medium: 900 ml of Phosphate Buffer pH 6.8 (Dissolve 6.8 gm. of Potassium Dihydrogen phosphate in water, dilute to 1000 ml with water and mix. Adjust the pH 6.8 with sodium hydroxide or 0.1M Hydrochloric acid)

Speed and Time: 50 RPM and 45 minutes

Withdraw a suitable volume of the medium and filter.

2.2 Diluent: Acetonitrile: Water: 50:50

2.3 Test Solution: Use the filtrate.

2.4 Reference Solution:

Empagliflozin Standard: Weigh about 28.0 mg WS in 100 ml volumetric flask. Dissolve by adding 60 ml of diluent and sonicate for 10 minutes. Cool to room temperature and make up the volume with diluent.

Linagliptin Standard: Weigh about 14.0 mg WS in 100 ml volumetric flask. Dissolve by adding 60 ml diluent and sonicate for 10 minutes. Cool to room temperature and make up the volume with diluent.

Combined standard solution:

(For 25/5 mg combination): Pipette 5 ml of Empagliflozin stock solution and 2 ml of Linagliptin stock solution into 50 ml volumetric flask and make up the volume with dissolution media.

(**For 10/5 mg combination**): Pipette 2 ml of Empagliflozin stock solution and 2 ml of Linagliptin stock solution into 50 ml volumetric flask and make up the volume with dissolution media.

Government of Nepal

Ministry of Health and Population Department of Drug Administration

National Medicines Laboratory

Quality and Method Validation Section

2.5 Procedure: Use the chromatographic system as described in the Assay using 20 µl as injection

volume. Inject the reference solution and the test solution.

Calculate the percent release of Empagliflozin and Linagliptin.

2.6 Limit: NLT 75 % (D) of the stated amount of Empagliflozin and NLT 80 % (D) of the stated amount of

Linagliptin.

3. Uniformity of Content:

Determine by liquid chromatography, as described in the Assay, using the following test solution.

3.1 Test Solution: Place one tablet in 100 ml completely dried volumetric flask. Add 60 ml of diluent

and sonicate for 15 minutes. Cool to room temperature, dilute with diluent to volume, and mix. Dilute 3

ml of filtrate to 25 ml with mobile phase.

3.2 Reference Solution: Same as assay.

4. Assay: *Determine by liquid chromatography*

4.1 Diluent: Acetonitrile: Water: 50:50

4.2 Test solution: Weigh and powder 20 tablets. Weigh accurately the powder equivalent to 15 mg of

Linagliptin and transfer into 100 ml of volumetric flask. Add 60 ml of diluent, sonicate for about 10

minutes, cool the solution to room temperature and make up the volume with diluents. Centrifuge or filter

the sample through Whatman No.1 filter paper. Dilute 2 ml to 50 ml with mobile phase. Filter the solution

through 0.2 m membrane filter.

4.3 Reference solution:

Empagliflozin Standard: Weigh about 30.0 mg WS in 100 ml volumetric flask. Dissolve by adding 60

ml of diluent and sonicate for 10 minutes. Cool to room temperature and make up the volume with

diluent.

Linagliptin Standard: Weigh about 15.0 mg WS in 100 ml volumetric flask. Dissolve by adding 60 ml

diluent and sonicate for 10 minutes. Cool to room temperature and make up the volume with diluent.

Combined standard solution:

Government of Nepal

Ministry of Health and Population **Department of Drug Administration**

National Medicines Laboratory

Quality and Method Validation Section

(For 25/5 mg combination): Pipette 5 ml of Empagliflozin stock solution and 2 ml of Linagliptin stock

solution into 50 ml volumetric flask and make up the volume with mobile phase, Filter the solution

through 0.2 membrane filter.

(For 10/5 mg combination): Pipette 2 ml of Empagliflozin stock solution and 2 ml of Linagliptin stock

solution into 50 ml volumetric flask and make up the volume with mobile phase, Filter the solution

through 0.2 membrane filter.

4.4 Chromatographic system:

Column: C18 (4.6mmX 150-mm, 5µ)

Flow rate: 1.0 ml/min

Wavelength: 227 nm

Injection volume: 20µl

Column Temperature: 30°C

Mobile Phase: A mixture of 70 volumes of Buffer and 30 volumes of Acetonitrile.

Buffer: Dissolve 5.444 gm. of Potassium dihydrogen orthophosphate in 1000 ml water.

Adjust pH to 4.0 with dilute orthophosphoric acid.

4.5 Procedure: Inject the reference solution five times and sample solutions. The test is not valid unless

the column efficiency is not less than 2000 theoretical plates, tailing factor is not more than 2.0, and the

relative standard deviation for replicate injection for each of the peaks is not more than 2.0%. Measure

the peak responses. Calculate the content of Empagliflozin and Linagliptin in Empagliflozin and

Linagliptin Tablets.

5. Other tests: As per pharmacopoeial requirements.